CSTL Q2 2026 Earnings Call Summary

Summary of Castle Biosciences Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Revenue: $103.5 million, a 20% increase compared to Q2 2025. Excluding DecisionDx-SCC and IDgenetix, revenue growth was 40%.
Test Volume: Core revenue drivers saw a 32% increase in test report volume year-over-year.
Gross Margin: 74.9%, down from 77.3% in Q2 2025. Adjusted gross margin was 76.3%, compared to 79.5% in the prior year.
Operating Expenses: Increased to $106.6 million from $90.4 million in Q2 2025, driven by higher sales and marketing costs.
Net Loss: $2.1 million, compared to net income of $4.5 million in Q2 2025. Diluted loss per share was $0.07.
Adjusted EBITDA: $12.4 million, up from $10.4 million in Q2 2025.
Cash Position: As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $266.8 million.

2. Strategic Updates and Business Highlights

Growth Strategy: Continued investment in commercial resources, clinical evidence generation, and expanding laboratory capacity.
Core Products:
- DecisionDx-Melanoma: 10,280 test reports, 3% growth year-over-year. Expected mid- to high single-digit growth for 2026.
- TissueCypher: 14,988 test reports, 63% growth year-over-year. Expected growth of 50%-52% for 2026.
- AdvanceAD-Tx: Over 1,000 orders received, recognized with a Genomics Innovation Award.
Clinical Evidence: New studies published supporting the effectiveness of DecisionDx-Melanoma in risk assessment.

3. Forward Guidance and Outlook

Revenue Guidance: Raised for 2026 to $365 million - $375 million, up from $345 million - $355 million.
Adjusted Gross Margin: Expected to remain in the low to mid-70s for the full year.
Positive Adjusted EBITDA: Anticipated for Q3, Q4, and the full year 2026.

4. Bad News, Challenges, or Points of Concern

Declining Metrics: Gross margin decreased compared to the previous year, indicating potential cost pressures.
Net Loss: Transition from profit to loss raises concerns about profitability amid increased expenses.
SCC Test Volume: Although there was a resurgence in SCC volumes, the company remains cautious about future reimbursement from Medicare contractors.
Competitive Pressures: The market for melanoma tests remains competitive, and the company is closely monitoring changes in the competitive landscape.

5. Notable Q&A Insights

AdvanceAD-Tx: The panel's unanimous vote for crosswalk to a reimbursement code was seen as a positive step, with expectations for a full commercial launch in early 2026.
TissueCypher ASP Trends: Some improvement noted, but not expected to continue at the same rate.
Sales Force Expansion: The company is focused on optimizing its sales force to maximize opportunities in both dermatology and gastroenterology.
Seasonality: The company noted that while there is some seasonality in test volumes, the overall trend for TissueCypher remains strong.
Future Pipeline: Continued investment in R&D is planned, with a focus on expanding existing therapeutic areas and developing new products.

Overall, Castle Biosciences reported strong growth in revenue and test volumes, while also navigating challenges related to profitability and competitive pressures. The raised revenue guidance and positive outlook for adjusted EBITDA reflect confidence in continued growth.

CSTL — Castle Biosciences, Inc.